Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of and cancer, will be hosting an analyst event on Tuesday, April 9, 2013, at 8:00 AM EDT in New York City. The meeting will focus on the development of TSO ( or CNDO-201) for the treatment of . The meeting will feature presentations by experts in the fields of immunology, , autism, psoriasis, and type 1 diabetes.

Physician expert speakers will include:

David E. Elliott, M.D., PH.D., James A. Clifton Chair of Gastroenterology and Director of the Division of Gastroenterology & Hepatology, University of Iowa Carver College of Medicine
Eric Hollander, M.D., Professor of Psychiatry and Behavioral Sciences, and Director, Autism and Obsessive Compulsive Spectrum Program, Montefiore Medical Center and the
Joshua R. Korzenik, M.D., Assistant Professor of Medicine, and the Director of the Brigham and Women’s Hospital Crohn’s and Colitis Center

Mark G. Lebwohl, M.D., Sol and Clara Kest Professor and Chairman, , Icahn School of Medicine at Mount Sinai
Desmond Schatz, M.D., Professor and Associate Chairman of Pediatrics, Medical Director of the and Director of the General Clinical Research Center, University of Florida

Read more:

Coronado Biosciences to Host Analyst Event in New York City
NASDAQ (press release)
The company’s two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, and multiple sclerosis and more »